47 results
S-8
EX-99.2
NTBL
Notable Labs Ltd
19 Apr 24
Registration of securities for employees
4:56pm
.
Approved 102 Awards may either be classified as Capital Gain Option (“CGO”) or Ordinary Income Option (“OIO”).
Approved 102 Awards elected
DEF 14A
NTBL
Notable Labs Ltd
16 Feb 24
Definitive proxy
9:00am
the approval of this Plan by the ITA.
Approved 102 Awards may either be classified as Capital Gain Option (“CGO”) or Ordinary Income Option (“OIO
PRE 14A
NTBL
Notable Labs Ltd
5 Feb 24
Preliminary proxy
5:00pm
, and shall be conditioned upon the approval of this Plan by the ITA.
Approved 102 Awards may either be classified as Capital Gain Option (“CGO”) or Ordinary
8-K/A
EX-99.2
NTBL
Notable Labs Ltd
29 Nov 23
Financial Statements and Exhibits
5:00pm
no restricted cash.
Marketable Securities
The Company’s investments in marketable securities have been classified and accounted for as available … income, net. All available-for-sale securities are considered available to support current operations and are classified as current assets.
Deferred
8-K/A
EX-99.4
66qp99q88v23xe
29 Nov 23
Financial Statements and Exhibits
5:00pm
424B3
2dxrt2x
5 Sep 23
Prospectus supplement
6:02pm
CORRESP
yxndcwln3cmjo7cm8
26 Jul 23
Correspondence with SEC
12:00am
UPLOAD
8k4pbwvdkkm1v psoos5
19 Jul 23
Letter from SEC
12:00am
S-4/A
e5xw9aj
30 Jun 23
Registration of securities issued in business combination transactions (amended)
4:38pm
S-4
0msahnecj0eg7hm4dg
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-10.17
62s5w8q3e rjnreuiv
11 May 23
Registration of securities issued in business combination transactions
9:09am
6-K
EX-99.2
6ldfkfp d2o0
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.2
x724x0cshtw2a9
15 Aug 22
VBL Therapeutics Announces Second Quarter 2022 Financial Results
4:07pm
6-K
EX-99.2
f14y420o6447dhu8
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am